Dechert Advises Poxel on $50M Non-Dilutive Financing Agreement With OrbiMed
October 03, 2024
October 03, 2024
PHILADELPHIA, Pennsylvania, Oct. 3 -- Dechert, a law firm, issued the following news:
Dechert has advised Poxel (Euronext: POXEL), a clinical-stage biopharmaceutical company, on its non-dilutive financing agreement with OrbiMed for US$50 million. This transaction monetizes a portion of Poxel's future royalties and sales-based payments from TWYMEEG(R) sales by Sumitomo Pharma in Japan.
The financing is set to bolster Poxel's strategic initiatives in rare diseases, reduce . . .
Dechert has advised Poxel (Euronext: POXEL), a clinical-stage biopharmaceutical company, on its non-dilutive financing agreement with OrbiMed for US$50 million. This transaction monetizes a portion of Poxel's future royalties and sales-based payments from TWYMEEG(R) sales by Sumitomo Pharma in Japan.
The financing is set to bolster Poxel's strategic initiatives in rare diseases, reduce . . .